Introduction {#s1}
============

Tauopathies are a group of dementias that have in common the formation of intracellular filamentous deposits seeded by the microtubule-associated protein tau, in abnormally hyperphosphorylated form(s). These disorders share a common disease mechanism and includes Alzheimer disease (AD), fronto-temporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis, cortical basal degeneration, dementia pugilistica, Pick's disease, progressive supranuclear palsy, tangle-only dementia, Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Tau inclusions are common among all of these tauopathies leading to diverse phenotypic manifestations, brain dysfunction, and degeneration. These diseases all implicate abnormal tau, with the absence of other disease-specific abnormalities (except in AD), in the onset and/or progression of disease.

Microtubule assembly is promoted and stabilized by the predominantly neuronal protein tau (Weingarten et al., [@B82]). In the central nervous system, tau has six isoforms derived from a single gene by alternative pro-mRNA splicing (Goedert et al., [@B39]; Himmler et al., [@B46]). In the human brain, tau isoforms range in size from 352 to 441 amino acids, with differences in the number of tubulin-binding domain repeats (R), three or four consisting of 31 or 32 amino acids near the C-terminus, or two, one, or no inserts of 29 amino acids near the N-terminus. Under normal conditions, tau is a phosphoprotein, in which isoform expression and degree of phosphorylation are developmentally regulated. However, in the disease state, tau has been found to be abnormally hyperphosphorylated and contains significantly higher phosphate content than the normal tau resulting from the phosphorylation at new sites on the protein (Kopke et al., [@B54]).

Axonal transport is essential to the growth and survival of a neuron throughout its life. Disruption of microtubules, as are observed in patients with AD, interrupts axonal transport which prevents vesicles and organelles from reaching the synapses. These result in the slow and steady deterioration of the synapses and retrograde degeneration. Mutations of *MAPT*, the tau gene, were discovered in 1998 and co-segregate with the disease in FTDP-17, providing unequivocal evidence that abnormalities in tau alone are enough to cause neurodegenerative disease (Hutton et al., [@B50]; Poorkaj et al., [@B65]; Spillantini et al., [@B72]). We have shown that hyperphosphorylation of tau can result in inhibition of microtubule assembly and can disrupt the preassembled microtubules *in vitro* (Alonso et al., [@B8], [@B5], [@B10]). Though the majority of evidence thus far supports the relationship of tau toxicity with disruption of the microtubule system, emerging evidence suggest that tau biological functions are not restricted to the cytoskeletal system: tau is present in the nuclei (Brady et al., [@B19]; Greenwood and Johnson, [@B42]; Frost et al., [@B34]; Multhaup et al., [@B62]; Bukar Maina et al., [@B20]) though this physiological function remains elusive; tau self-acetylation activity has been described but physiological consequences of this modification remains uncertain (Cohen et al., [@B25]); tau has also been shown to be present in the dendrites under pathological conditions and impair synaptic function (Hoover et al., [@B47]). More recently, the idea of tau transmitting the disease as a prion-like protein is becoming more attractive. As tau is found in the extracellular space and can be uptaken by neighbor neurons, this tau-mediated pathway might represent an attractive model of therapeutical target to halt neurodegeneration. In this review article, we will discuss the putative mechanisms of tau-induced neurodegeneration in light of the current knowledge and our own experience with tau models.

Tau: Pathological Gain of Function {#s2}
==================================

Tau Isoforms and Post-translational Modifications {#s2-1}
-------------------------------------------------

The gene for tau, *MAPT*, is located on chromosome 17q21.1. It is a single copy gene which undergoes alternative splicing to generate six isoforms found in the human brain (as reviewed in Andreadis, [@B12]). The number of N-terminal inserts can vary (0N, 1N, or 2N) as well as the number of C-terminal repeats (3R or 4R). These repeats are located in the microtubule binding domain (MTBD), which can lead to differential polymerization rates when mixed with tubulin. When analyzed in microtubule polymerization reactions, recombinant proteins representing each of these six tau isoforms and the 3R proteins had slower rates of polymerization than 4R proteins independently of the N-terminal composition (Goedert and Jakes, [@B37]). The 4R and 3R isoforms of tau can be found in an approximately 1:1 ratio in normal adult brains with the 1N form at the highest level (50%), 0N (40%) and 2N (10%; Higuchi et al., [@B45]). Each of the six isoforms have been found in the brains of AD and other tauopathies (including Downs Syndrome, amyotrophic lateral sclerosis, Niemann-Pick disease Type C and some FTDP-17 mutations) at similar ratios as normal brains (Higuchi et al., [@B45]; Connell et al., [@B26]). Other tauopathies, including cortical basil degeneration, progressive supranuclear palsy, and other FTDP-17 mutations, appear to express more 4R proteins than 3R proteins at both the mRNA and protein levels (Higuchi et al., [@B45]; Connell et al., [@B26]). Brains from Pick's Disease patients show higher 3R levels than 4R in the sarkosyl insoluble fractions, and this change in the ratio appears to occur post-transcriptionally (Higuchi et al., [@B45]; Connell et al., [@B26]).

Tau function is modulated by many post-translational modifications (PTMs) including, but not limited to, phosphorylation, acetylation, ubiquitination and protein fragmentation (as reviewed in Beharry et al., [@B16]; Alonso et al., [@B1]). As the review of all of tau PTMs is extremely challenging due to the large number of modified sites and by the coexistence of multiple types of modifications, this review article will focus on how tau changes due to phosphorylation can affect microtubule stability and regulate not fully elucidated tau functions. Many of the PTMs lead to changes in the interaction of tau with other molecules by changing the charge of an amino acid, or by removing a section of the protein as occurs in fragmentation. The cleavage of tau by calpains and/or caspases can result in molecules that are aggregate-prone which can cause other full-length tau molecules to aggregate with it (Chung et al., [@B24]; Gamblin et al., [@B35]; Guillozet-Bongaarts et al., [@B43]; Mondragón-Rodríguez et al., [@B58],[@B59]).

Microtubules and Tau in Alzheimer's Disease {#s2-2}
-------------------------------------------

In neurons from patients with AD, there is a decrease in microtubules and a several-fold increase in the concentration of tau (Kopke et al., [@B54]). There are three different pools of tau in the brains of AD patients: AD tau is most similar to normal tau and is not hyperphosphorylated; AD Phosphorylated tau (AD P-tau) is soluble hyperphosphorylated tau; and paired helical filaments (PHFs)-tau is insoluble and hyperphosphorylated. AD tau in AD brains is decreased by about 60% compared to tau found in normal brain. AD P-tau, as well as normally phosphorylated tau, can be isolated from AD brain in solution (Kopke et al., [@B54]). Analyzing microtubule-promoting activity of tau from AD brains, we found that AD tau has normal activity in *in vitro* assembly of microtubules assays. Conversely, AD P-tau did not promote microtubule assembly but this activity was recovered upon dephosphorylation with alkaline phosphatase treatment (Alonso et al., [@B8]; Figure [1](#F1){ref-type="fig"}). Interestingly, we found that AD P-tau inhibited the microtubule assembly promoted by normal tau, MAP1 and MAP2 (Alonso et al., [@B5]). Pre-incubation of AD P-tau with normal tau prior to the addition to tubulin inhibited not only the normal tau-microtubule--promoting activity but also destroyed microtubules already present. This was probably due to interactions between tau and AD P-tau resulting in the sequestering of normal tau from the tubulin, and suggesting that AD P-tau has prion-like activity.

![Microtubule disruption can be caused by hyperphosphorylation of tau. **(A)** Electron micrographs showing the products of microtubule assembly. The microtubules were negatively stained with phosphotungstic acid. Rat brain tubulin was placed in an *in vitro* reaction in the presence of **(a)** control acid-soluble tau, **(b)** Alzheimer disease (AD) acid-soluble tau, **(c)** AD Phosphorylated tau (AD P-tau) and **(d)** AD P-tau after dephosphorylation. Very few microtubules were observed in the presence of AD P-tau and dephosphorylation appears to slightly rescue microtubule disruption (Alonso et al., [@B8]). **(B)** Cartoon model of microtubule disruption due to P-tau sequestration of normal tau away from the tubulin resulting in instability and loss of cytoskeletal structure. Image reproduced as authorized by the editors of Alonso et al. ([@B1]).](fncel-12-00338-g0001){#F1}

AD P-Tau Has Prion-Like Properties {#s2-3}
----------------------------------

The ability of AD P-tau to bind normal tau was verified using a solid phase binding assay (Alonso et al., [@B4]). Quantitation of this binding was performed using an *in vitro* assay in solution and we observed that the binding of AD P-tau to normal tau was non-saturable (Alonso et al., [@B4]). Furthermore, analysis by electron microscopy indicated that the products of these reactions were bundles of filaments (Alonso et al., [@B4]). Based on these results, we hypothesized that the hyperphosphorylation of tau changed its conformation in such a way that this change could be transferred to the normal protein, acting as a prion-like molecule to seed pathological tau self-assembly. The ability of hyperphosphorylated tau to bind normal tau was also observed in yeast, a less complex cellular model (Vandebroek et al., [@B78]). Expression in yeast of the human four-repeat and three-repeat isoforms demonstrated that these isoforms became phosphorylated at pathological sites and assumed a pathological conformation resulting in aggregate formation. The phosphorylation was modulated by yeast kinases Mds1 and Pho85, orthologs of GSK-3β and cdk5. The Van Leuven group observed many biochemical characteristics similar to those we had already observed with human tau including a positive correlation between tau aggregation and phosphorylation; slower mobility in SDS-PAGE with increased phosphorylation; increase in the formation of filaments with isolated hyperphosphorylated tau, and induction of nucleation, or seeding, of normal-non-P-tau assembly by this hyperphosphorylated tau (Vandebroek et al., [@B78]). The prion-like properties of hyperphosphorylated tau are due to its biochemical stability, which promotes the aggregation of tau, and are consistent with our observations using hyperphosphorylated tau isolated from Alzheimer brain (Alonso et al., [@B4]). The conformational change transfer by AD P-tau to normal tau is similar to a property of a prion protein. We were the first to link hyperphosphorylation of tau to these nucleation properties of tau (Alonso et al., [@B8], [@B5], [@B9]).

Hyperphosphorylation Induces Prion-Like Tau Self-Assembly {#s2-4}
---------------------------------------------------------

In AD progression, tau becomes hyperphosphorylated prior to the appearance of neurofibrillary tangles (Bancher et al., [@B13]). Hyperphosphorylated tau shows a 2-3-fold increase in the number of moles of phosphate per mole of protein (Kopke et al., [@B54]) which results from the appearance of new phosphorylated sites. The increase in phosphorylation can lead to neuronal degeneration triggered by tau self-assembly into tangles composed of PHFs and straight filaments (SFs). In *in vitro* assays at varying pHs, AD P-tau self-assembled into tangles of PHFs mixed with SFs (Alonso et al., [@B10]). The PHFs generated were \~20 nm wide which narrowed to \~10 nm at approximately every 80 nm similar to those of AD PHFs. Within the PHFs, protofilaments (4 nm) and SFs (\~15 nm) were observed, also similar to those found in AD. Dephosphorylation of AD P-tau inhibited the self-assembly of tau (Alonso et al., [@B8]), suggesting that hyperphosphorylation was required for filament formation.

Tau intermolecular association leading to self-assembly appears to occur through the MTBD, whereas the flanking regions can inhibit these interactions (von Bergen et al., [@B79]; Pérez et al., [@B64]; Alonso et al., [@B7]). These tau regions have concentrated positively charged residues, and we postulate that these patches might be responsible for the inhibition of tau self-assembly. Supporting this idea, when two N-terminal inserts of tau, which are highly negative, are present, tau self-assembly is induced (Alonso et al., [@B10]). Phosphorylation of tau, which introduces negative charges in these regions, results in tau molecules that acquire the ability to bind normal tau. Tau-tau interactions begin to form when there are \~4 moles of phosphate per mole of protein, polymerization of tau leading to fibril formation begins when there are \~10 moles of phosphate per mole of protein (Alonso et al., [@B10], [@B7]). From these results, we understand that there are at least two different conformational states of tau induced by differential phosphorylation. Similar results are observed by the oxidation of tau by carbonyl addition to Lys residues, which changes positively charged residues to negatively charged ones under oxidative-stress conditions (Santa-María et al., [@B69]). Consistent with this model, tau molecules modified by truncation, which eliminates the positive fragment, can also induce tau self-assembly (Zhou et al., [@B84]). In this context, when polyanions are used to induce aggregation, such as RNA, polyGlu, or heparin, it would not be surprising that certain phosphorylation sites appeared to be inhibitory of tau aggregation (Schneider et al., [@B71]).

To further understand these structural characteristics of tau, six isoforms of tau were expressed heterologously, phosphorylated by treatment with normal brain extract which contains the kinases and we followed their ability to bind normal tau and to inhibit microtubule-promoting activity (Alonso et al., [@B9],[@B10]). Proteins treated with rat brain extract became hyperphosphorylated, \~12 moles phosphate per mole of protein (P-tau), which is similar in phospho-level to AD P-tau. These hyperphosphorylated recombinant proteins were able to self-assemble into tangles of PHFs/SFs (Alonso et al., [@B9],[@B10]) and inhibit microtubule assembly activity (Alonso et al., [@B10]). Interestingly, the presence of FTDP-17 mutations on tau also induced conformational changes (Jicha et al., [@B52]), decreased the formation of microtubules (Bunker et al., [@B21]), and/or increased the ability of tau to self-assemble (Goedert et al., [@B38]). To analyze why these mutations may alter tau activity in a similar manner as phosphorylation, we generated recombinant tau proteins containing FTDP-17 mutations (R406W, P301L, V337M, or G272V) and incubated in brain extract as above (Alonso et al., [@B7]). The results showed that the presence of these mutations increased the rate and extent of phosphorylation (\~16--18 moles of phosphate per mole of protein), suggesting that the mutations induced the conformational changes described above (Alonso et al., [@B7]). These results indicate that the mutated tau molecules are better substrates for kinases than wild-type tau. This effect was observed by another group that reported higher phosphorylation at Ser202 in FTDP-17 mutant tau (Han et al., [@B44]). Furthermore, these tau mutants showed filament at lower mole amounts of phosphate per mole of protein (Alonso et al., [@B7]).

Together, our studies indicate that hyperphosphorylation confers upon tau a toxic property, due to its ability to bind normal tau and MAPs. However, we have previously shown that tau filaments do not inhibit microtubule assembly and do not bind other MAPs potentially due to the neutralization of the tau peptide involved in tau self-assembly (Ganguly et al., [@B36]) by intermolecular interactions (Alonso et al., [@B6]). Consistent with this, morphometric study of brain biopsy specimen shows that the decrease in microtubule density in AD patients was unrelated to PHF accumulation (Cash et al., [@B22]). In aged tau transgenic mice from Takashima's group, synapse loss was found in the same brain region as hyperphosphorylated tau (Kimura et al., [@B53]). Based on these findings, we hypothesize that once tau becomes hyperphosphorylated it can bind normal MAPs and disrupt microtubules, resulting in the interruption of axoplasmic transport and in synaptic degeneration. However, upon tau self-assembly, there will be no contact region for normal MAPs thereby no disruption of the microtubule network and axonal transport. This model is in agreement with the results of the European Tau meeting held last year that has determined that in tauopathies, tau in aggregates is always hyperphosphorylated (Mudher et al., [@B61]).

What Is Hyperphosphorylated Tau? How Can We Study the Gain of Toxic Function? {#s2-5}
-----------------------------------------------------------------------------

Though the defect in tau that leads to aggregation and neurodegeneration is commonly referred to as hyperphosphorylated tau, its definition is still unclear. The debate is whether tau toxic effect is due to a general increase in moles of phosphate per mole of protein regardless as to where these modifications are or whether there is a need for phosphorylation at specific sites within a molecule. Long-range interaction in tau, and other intrinsically disordered proteins (IDPs), are modulated by intra- and inter-molecular interactions and by PTMs, such as phosphorylation, acetylation and others (Bibow et al., [@B18]). As an IDP, the secondary structure of tau is not defined, however, tau structural information is very important in the formation of PHF/SF in AD brains (Fitzpatrick et al., [@B32]). This indicates that our observations on tau self-assembly using the whole molecule hold more weight than those using different fragments of tau. The regions N-terminal to the MTBD are very basic with a pI of more than nine and are separated from other parts of the protein by Pro residues which are known to introduce kinks in protein structure (Figure [2A](#F2){ref-type="fig"}). The positive charges in this region can mask the negative charges in the MTBD to limit intermolecular interactions. At the start of tau polymerization, three residues in this basic region (Thr212, Thr231 and Ser262) have been shown to be at least 50% phosphorylated, decreasing the pI of the region (Alonso et al., [@B7]). On the C-terminal side of the MTBD, there is a second basic region and phosphorylation of Ser396 and/or Ser404 may also change the pI, increasing the potential for intermolecular interactions leading to tau self-assembly.

![Pathological human tau (PH-Tau) mimics AD P-tau. **(A)** A hypothetical scheme of the phosphorylation-induced self-assembly of wild-type (left) and fronto-temporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) mutated tau proteins (right). Tau self-assembles mainly through the microtubule binding domain (MTBD)/repeat R2 and R3. The β-structure of R2 and R3 is depicted at the cartoon on the bottom. Regions of tau molecule both N-terminal and C-terminal to the repeats are inhibitory of self-assembly. Hyperphosphorylation of tau neutralizes these basic inhibitory domains, enabling tau-tau interaction. The C-terminal region beyond Pro397 (398--441) is a highly acidic segment masks the repeats. Phosphorylation of tau at Ser396 and/or Ser404 opens this segment, allowing tau-tau interaction through the repeats. FTDP-17 mutations make tau a more favorable substrate for phosphorylation than the wild-type tau. The mutated tau proteins achieve the conformation required to self-assemble at a lower level of incorporated phosphate. Although the FTDP-17 mutant tau proteins have conformations that are more prone to polymerize, in the absence of hyperphosphorylation, the highly basic segments and the C-terminus interfere with polymerization. Phosphorylation sites are indicated by *red P*s at Ser/Thr positions in tau (left panel): 199, 202, 205, 212, 231, 235, 262, 396, 404 and 422; and in FTDP-17 mutant tau (right panel): 199, 212, 231, 262 and 396, respectively. Image taken from Alonso et al. ([@B7]). The Tau cartoon at the bottom indicates the pseudophosphorylated version of tau that is used in our studies, PH-Tau (Di et al., [@B29]). **(B)** AD P-tau inhibits regeneration of microtubules. To induce microtubule assembly 3T3 cells expressing AD P-tau were incubated with 15% fresh rat brain cytosol in buffer containing 1 mM GTP for 1 h at 37°C. Cells were processed for immunofluorescence staining by using DM1-A Ab against tubulin (green) and 134d rabbit polyclonal Ab against tau (red). AD P-tau, but not normal tau, inhibited microtubule assembly (Alonso et al., [@B6]). **(C)** PH-Tau, as AD P-tau, inhibits microtubule assembly when expressed in cells. CHO cells were transfected with either tau, PH-Tau on the normal tau background (PH-Tau(n)), or PH-Tau on the R406W background. After 48 h, the cells were permeabilized with 0.1% Nonidet P-40 before fixing and then processed for immunocytochemistry as described in **(B)**. Merge is shown in yellow. Bar, 25 μm (Alonso et al., [@B3]). This research was originally published by Alonso et al. ([@B3]).](fncel-12-00338-g0002){#F2}

Cells treated with AD P-tau showed decreased microtubule stability (Alonso et al., [@B6]; Figure [2B](#F2){ref-type="fig"}). Based on our knowledge of phosphorylation events in AD brains, we used phosphomimetics, with and without the FTDP-17 mutation R406W, to determine whether hyperphosphorylation was site-specific. Residues that were determined to have about five moles of phosphate incorporated per mole of protein when self-assembly occurred were changed to Glu to mimic the negative charge of phosphorylation or to Ala as a non-phosphorylatable control. During the initial analysis, nine sites were found to fit the criteria described above Ser199, Ser202, Ser205, Thr212, Thr231, Ser235, Ser262, Ser396 and Ser404. Vectors were generated by site-directed mutagenesis and then transfected into mammalian cells. Tau proteins containing the Ala mutations expressed in cell lines acted similarly to wild-type tau. Conversely, for most of the Glu mutations some tau dissociation from tubulin was observed, but none exhibited complete microtubule disruption (Alonso et al., [@B3]). Therefore, single phosphorylation events did not appear to change the charge of the molecule enough to convert tau into an AD P-tau like toxic molecule. To try to mimic the toxic nature of tau, double and triple mutant proteins were expressed in cells, and the triple combination of T212E/S235E/S262E was observed to bind weakly to microtubules with a concomitant decrease in tubulin staining. Furthermore, the triple mutant protein aggregated in the cytoplasm and nuclear space and sequestered normal tau similarly to AD P-tau *in vitro* (Alonso et al., [@B3]; Figure [2C](#F2){ref-type="fig"} compared to Figure [2B](#F2){ref-type="fig"}). A fourth residue, Ser199, was found to be highly phosphorylated in the pseudophosphorylated tau compared to wild-type, suggesting that phosphorylation at this fourth site was able to convert tau into a molecule that had gained toxic function. This toxicity was enhanced by the FTDP-17 mutation R406W (Figure [2C](#F2){ref-type="fig"}). For our future work, we have focused on a molecule called Pathological Human tau (PH-Tau) containing the phosphomimetics of tau at these four sites (S199, T212, T231 and S262) with the R406W mutation.

Models Used to Study the Role of Tau in AD and Other Neurodegenerative Disorders {#s2-6}
--------------------------------------------------------------------------------

Human tau has been overexpressed in many mouse models which have been shown to reproduce the cognitive impairment found in AD (Berger et al., [@B17]; Eckermann et al., [@B30]; Lasagna-Reeves et al., [@B55]; Roberson et al., [@B67]; Sydow et al., [@B74]; Webster et al., [@B80]) and neuronal death[^1^](#fn0001){ref-type="fn"}. The level of heterologous tau expression in many of these models is very high compared to levels of endogenous tau which could lead to mechanistic differences in the analysis of the neurons. Furthermore, the analysis gets more complicated since tau has six isoforms, many of these models express variations of human tau, with or without mouse tau, and with or without FTDP-17 mutations (Lewis et al., [@B57], [@B56]; Tanemura et al., [@B75], [@B76]; Tatebayashi et al., [@B77]; Santacruz et al., [@B68]; Schindowski et al., [@B70]; Yoshiyama et al., [@B83]; Hundelt et al., [@B49]; Flunkert et al., [@B33]). Neurodegeneration is observed in most of these models, but these mice also have phenotypes not commonly found in AD, i.e., motor deficiencies due to tau accumulation in the spinal cord (Lewis et al., [@B57]; Yoshiyama et al., [@B83]). Many groups have switched to the TetOff system to better regulate tau expression levels and localization. This system utilizes the Calmodulin Cam kinase II promoter which leads to expression in the neurons and can be regulated using doxycycline in the diet (Tatebayashi et al., [@B77]; Hundelt et al., [@B49]). Tau expressed in most of these model systems become phosphorylated at common Ser/Thr residues that can be linked to pathogenic phosphorylation sites found in AD as compiled by the Hanger group[^2^](#fn0002){ref-type="fn"}.

A top priority in the research of neurodegenerative disease is the development of therapeutics. The mouse models that are generated to express tau phosphomimetics may be a useful tool in developing and analyzing new treatments for dementia related to the hyperphosphorylation of tau. However, as described above, one must be careful to use pseudophosphorylation patterns that induce similar conformational changes in tau to those observed in AD P-tau. For example, a mouse model of hyperphosphorylation which studied a tau molecule containing 10 different pseudophosphorylated residues was generated with no cognitive impairment or neurodegeneration observed (Hundelt et al., [@B49]). Conversely, our studies, including cell and neuronal culture, *Drosophila*, and a mouse model, which target four specific sites (S199, T212, T231 and S262) on tau resulted in cell death in culture and neurodegeneration and learning deficiencies in *Drosophila* and mice (Alonso et al., [@B3]; Beharry et al., [@B15]; Di et al., [@B29]). Furthermore, we showed that the toxic effect was stronger when the sites chosen for pseudophosphorylation were paired with the FTDP-17 mutation R406W (Alonso et al., [@B3]; Beharry et al., [@B15]). In our mouse model that uses the TetOff system, we found that PH-Tau was expressed in the forebrain of the mouse and resulted in the formation of aggregates, synaptic disruption, neurodegeneration, astrocytosis and cognitive decline (Di et al., [@B29]; Figure [3](#F3){ref-type="fig"}). In this model, PH-tau expression is regulated by the addition (suppressed) or removal (induced) of doxycycline to/from the food and/or water of these animals. When expression was induced, levels of PH-Tau increased up to 14% of total tau protein (i.e., 14 molecules of PH-Tau per 100 molecules of murine tau) and aggregates were detected. When expression was suppressed, there were baseline levels of PH-Tau observed. At this low level, PH-Tau was detected biochemically as oligomers and triggered early cognitive deficits (Figure [3A](#F3){ref-type="fig"}), and loss of synapses in the hippocampus as determined by decreases in synaptic protein levels and quantitation of electron micrographs (Figures [3B,C](#F3){ref-type="fig"}). While PH-Tau was barely detectable by immunohistochemistry in tissue sections from these animals, some PH-Tau was observable and appeared to have translocated in the nucleus. Dramatic neuronal loss was not observed in those animals (Figure [3D](#F3){ref-type="fig"}), but the synaptic changes suggest that at low levels the effect of abnormal tau expression might not be related to changes in the cytoskeleton but to its presence in the nucleus and regulation of protein expression. Interestingly, when PH-Tau expression was induced, cognitive decline was somewhat rescued (Figure [3A](#F3){ref-type="fig"}), the oligomeric forms of PH-Tau decreased but the sarkosyl-insoluble tau increased, and the decrease of synaptic proteins and synaptic terminals appeared to be reversed (Figures [3B,C](#F3){ref-type="fig"}). We can speculate that at higher levels, PH-Tau begins to seed a larger amount of self- aggregation as observed by the formation of sarkosyl-insoluble tau and that this may prevent the toxic protein from entering the nucleus. In fact, tau localization was observed in the perinuclear region of the neurons compared to the nuclear localization in the low expressing brains (data not shown). Neuronal death increased in both the CA1 and CA3 regions of the hippocampus from the mice in which PH-Tau expression was induced (Figure [3D](#F3){ref-type="fig"}). By increasing the expression of PH-Tau, which resulted in the increase of its aggregation propensity into sarkosyl insoluble aggregates, the impairment of cytoskeletal function begins potentially by the sequestering of normal tau from the microtubules, thereby increasing their instability (Di et al., [@B29]). These results are comparable to the effects of hyperphosphorylated tau in the brains of AD patients. Based on these different observations, it appears that the specific sites that are phosphorylated or modified, rather than the number of sites, may be an important factor in tau toxicity.

![Characterization of PH-Tau mouse model. **(A)** Bigenic mice (12-month old) were tested for behavior deficits in the Novel Object Recognition task. Significant decreases in spatial memory and memory storage were observed. **(B)** PH-Tau~low~ mice shows significant loss of synapses, decreased post-synaptic density and enlarged pre-synaptic portion. Decrease in the length of the post-synaptic density was observed in both PH-Tau~low~ and PH-Tau~high~ mice. Synapses in CA1 stratum radiatum area are shown in the magnified images of square boxes. Quantitation of the number of synapses in the CA1 stratum radiatum area is shown in the bottom of the figure. **(C)** Representative Western blot of mouse hippocampus homogenate. The levels of synaptophysin, PSD95 and β-III-tubulin were measured. Loss of synaptic proteins was observed in PH-Tau~low~ mice. **(D)** Coronal slices of hippocampus stained with antibody NeuN recognizing nucleus of neurons (Left). Scale bar = 50 μm. Counts of the NeuN positive cells in both the CA1 and CA3 regions. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001; right; Di et al. [@B29].](fncel-12-00338-g0003){#F3}

Conclusions and Future Directions {#s3}
=================================

It is apparent that tau hyperphosphorylation is an early event in the disease progression for AD and other tauopathies, though there are other modifications that can also affect the protein. From all that we have learnt through our research and those of our fellow scientists, we can propose that these modifications of tau can modulate different events at the cellular levels with important consequences for its physiology (Figure [4](#F4){ref-type="fig"}), including converting the protein from a microtubule stabilizer to a microtubule disrupter inducing a pathological state. Changes in the cytoskeleton might not be the only effect of these mdifications on tau. In our lab, tau has been observed to translocate into the cell nucleus (Alonso et al., [@B3]; Di et al., [@B29]). Though tau has been shown to interact with nuclear DNA, hyperphosphorylation can alter this interaction with potential changes at the chromatin and transcriptional level, thereby changing its physiological role (Hua and He, [@B48]; Wei et al., [@B81]; Padmaraju et al., [@B63]; Sultan et al., [@B73]; Qi et al., [@B66]). Our preliminary studies suggest that tau in the nucleus may also be involved in the regulation of mRNA stability, which would result in potential changes at the transcriptome and proteome by regulating gene expression, thus affecting cellular function during the progression of neurodegeneration. We have recently found that tau can associate with factors involved in mRNA 3′ processing, such as the tumor suppressor p53 (Devany et al., [@B28]) and PARN deadenylase (Cevher et al., [@B23]), and that the formation of tau/p53/PARN complex(es) in the nucleus can regulate mRNA 3′ end processing. Interestingly, these interactions are regulated by tau phosphorylation state (Baquero et al., [@B14]). These changes might happen at very early stages of disease progression.

![Proposed mechanisms of neurodegeneration. **(A)** Hyperphosphorylation of tau affects multiple cellular processes. PH-tau aggregates are formed when the balance between kinases and phosphorylases is disrupted. The aggregates can begin to disrupt the stability of the microtubules. This toxic molecule has also been shown to translocate into the nucleus, cause intracellular degeneration, protein aggregation and vacuole formation. The presence of tau in the nucleus might be involved in alterations of protein expression. Disruption of the actin cytoskeleton can lead to membrane zeiosis and tau can be released from the cells, potentially propagating the disease to neighboring cells. Image reproduced from Alonso et al. ([@B1]). Permissions were obtained through RightsLink License Number: 4358781157689. **(B)** Left panel: low level of PH-tau expression results in translocation to the nucleus, synaptic dysfunction and mitochondrial disruption. The presence of tau in the nucleus might be involved in alterations of protein expression. Right panel: high levels of PH-Tau expression results in protein aggregation, microtubule disruption and loss of synapses. Loss of cytoskeletal stability leads to neurodegeneration (Alonso et al., [@B2]). Permission granted to reproduce figure from Alonso et al. ([@B2]).](fncel-12-00338-g0004){#F4}

We have described above how hyperphosphorylated tau can destabilize the microtubules but it can also interact with actin causing a destabilization of these microfilaments (Elie et al., [@B31]). Disruption of the microfilaments can lead to zeiosis of the cell membrane due to their important role in membrane stability. We have observed that as membrane pinches off during exocytosis, there is a release of hyperphosphorylated tau within the vesicles. These tau-containing vesicles have the potential to be taken up through endocytosis, or some other mechanism, into neighboring cells. We were the first to show that hyperphosphorylated tau sequesters healthy tau protein causing it to take on the toxic function of the pathological protein (Alonso et al., [@B4]). These findings support the prion-like nature of hyperphosphorylated tau which can spread its pathology to surrounding cells by moving from cell to cell and sequestering healthy tau which causes a disruption of all cytoskeleton components, destabilization of the organelles, disruption of protein synthesis and eventually zeiosis induction.

Zeiosis of the cell membrane is expected to release hyperphosphorylated tau-containing membrane vesicles. While we do not know the physiological role, if any, of tau in the extracellular space, it is possible that soluble hyperphosphorylated tau is uptaken by non-affected neurons through its interaction with the muscarinic receptor triggering the signal transduction pathway (Gómez-Ramos et al., [@B40], [@B41]). Supporting this model, our preliminary results indicate that the muscarinic receptors are involved in tau's uptake (Morozova et al., [@B60]). It is also possible that hyperphosphorylated tau-containing membrane vesicles are taken up by endocytosis by surrounding cells. This model of tau transmission might be therefore addressed with immunotherapy (Iqbal et al., [@B51]).

Different scenarios can be considered where the levels of hyperphosphorylated tau begin increasing to toxic levels due to kinase overactivity, phosphatase deficiency, failure in the clearance system or a combination of these and others. Early in disease progression, modified tau may translocate into the nucleus, move to synapses, or interfere with mitochondrial homeostasis (Figure [4B](#F4){ref-type="fig"}, left). Any or all of these physiological changes could lead to cognitive impairment without significant structural changes, as observed in our mouse model under conditions of low PH-Tau expression (Di et al., [@B29]). As disease progression continues, the levels of pathological tau tend to increase in the neurons to levels that begin to disrupt microtubule stability and other cytoskeletal components which can trigger retrograde neurodegeneration (Figure [4B](#F4){ref-type="fig"}, right). Despite these different mechanisms, it appears that therapeutics to reduce the levels of hyperphosphorylated tau as well as therapeutics aimed at preventing cytoskeleton disruption remain as key targets for tauopathies (Corbo and Alonso, [@B27]). The development of combination therapies that address the multiple physiological changes induced by hyperphosphorylated tau may help to unravel the process of neurodegeneration and reduce the number of patients affected.
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